NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE
Disclosed herein is novel crystalline forms of Valsartan namely, a crystalline form designated as Form A, and its solvates thereof, novel crystalline form of Valsartan designated as Form B and solvates thereof, novel crystalline form of Valsartan designated as Form C and solvates thereof, novel crys...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DOSHI, VAIBHAV, CHINUBHAI KUMAR, ASHOK BHAYANI, PRITI, JAYESH JHA, MUKESH, SUBHODH NIMBALKAR, MANMOHAN, MADHAVRAO |
| description | Disclosed herein is novel crystalline forms of Valsartan namely, a crystalline form designated as Form A, and its solvates thereof, novel crystalline form of Valsartan designated as Form B and solvates thereof, novel crystalline form of Valsartan designated as Form C and solvates thereof, novel crystalline form of Valsartan designated as Form D and its solvates thereof, processes for their preparation, pharmaceutical compositions containing these polymorphs and their use in medicine. The present invention further discloses a novel process for preparing a stable amorphous form of Valsartan and in this connection to amorphous form of Valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of Valsartan.
L'invention concerne de nouvelles formes cristallines de valsartan, soit une forme cristalline désignée sous le nom de forme A et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme B et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme C et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme D et ses solvates, des procédés pour leur préparation, des compositions pharmaceutiques contenant ces polymorphes ainsi que leur utilisation en médecine. La présente invention concerne également un nouveau procédé destiné à préparer une forme amorphe stable de valsartan et, dans ce contexte, une forme amorphe de valsartan produite au moyen de ces procédés. La présente invention concerne en outre un nouveau procédé destiné à obtenir des cristaux stables de forme I de valsartan. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2007017897A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2007017897A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2007017897A33</originalsourceid><addsrcrecordid>eNqNjb8KwjAYxLs4iPoOAQfr8EH_KNUxLSkppPlCGtQoUorESbRQd1_diD6A03HH7-7GwUvijglSaNsYKkQlGSlR1w3BkoTNEiSEMRRU53iwkEDNDLcClEYFMVjxARSThkr0sYRTsvAFDoYZTY8oYP2B8goUZ9ITK2-_G2egtX-bBqNrdxvc7KeTYF4yU3Bw_aN1Q99d3N092z0mUZRFcbbZZjRN_6PehBI78w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE</title><source>esp@cenet</source><creator>DOSHI, VAIBHAV, CHINUBHAI ; KUMAR, ASHOK ; BHAYANI, PRITI, JAYESH ; JHA, MUKESH, SUBHODH ; NIMBALKAR, MANMOHAN, MADHAVRAO</creator><creatorcontrib>DOSHI, VAIBHAV, CHINUBHAI ; KUMAR, ASHOK ; BHAYANI, PRITI, JAYESH ; JHA, MUKESH, SUBHODH ; NIMBALKAR, MANMOHAN, MADHAVRAO</creatorcontrib><description>Disclosed herein is novel crystalline forms of Valsartan namely, a crystalline form designated as Form A, and its solvates thereof, novel crystalline form of Valsartan designated as Form B and solvates thereof, novel crystalline form of Valsartan designated as Form C and solvates thereof, novel crystalline form of Valsartan designated as Form D and its solvates thereof, processes for their preparation, pharmaceutical compositions containing these polymorphs and their use in medicine. The present invention further discloses a novel process for preparing a stable amorphous form of Valsartan and in this connection to amorphous form of Valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of Valsartan.
L'invention concerne de nouvelles formes cristallines de valsartan, soit une forme cristalline désignée sous le nom de forme A et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme B et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme C et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme D et ses solvates, des procédés pour leur préparation, des compositions pharmaceutiques contenant ces polymorphes ainsi que leur utilisation en médecine. La présente invention concerne également un nouveau procédé destiné à préparer une forme amorphe stable de valsartan et, dans ce contexte, une forme amorphe de valsartan produite au moyen de ces procédés. La présente invention concerne en outre un nouveau procédé destiné à obtenir des cristaux stables de forme I de valsartan.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20091015&DB=EPODOC&CC=WO&NR=2007017897A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20091015&DB=EPODOC&CC=WO&NR=2007017897A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DOSHI, VAIBHAV, CHINUBHAI</creatorcontrib><creatorcontrib>KUMAR, ASHOK</creatorcontrib><creatorcontrib>BHAYANI, PRITI, JAYESH</creatorcontrib><creatorcontrib>JHA, MUKESH, SUBHODH</creatorcontrib><creatorcontrib>NIMBALKAR, MANMOHAN, MADHAVRAO</creatorcontrib><title>NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE</title><description>Disclosed herein is novel crystalline forms of Valsartan namely, a crystalline form designated as Form A, and its solvates thereof, novel crystalline form of Valsartan designated as Form B and solvates thereof, novel crystalline form of Valsartan designated as Form C and solvates thereof, novel crystalline form of Valsartan designated as Form D and its solvates thereof, processes for their preparation, pharmaceutical compositions containing these polymorphs and their use in medicine. The present invention further discloses a novel process for preparing a stable amorphous form of Valsartan and in this connection to amorphous form of Valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of Valsartan.
L'invention concerne de nouvelles formes cristallines de valsartan, soit une forme cristalline désignée sous le nom de forme A et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme B et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme C et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme D et ses solvates, des procédés pour leur préparation, des compositions pharmaceutiques contenant ces polymorphes ainsi que leur utilisation en médecine. La présente invention concerne également un nouveau procédé destiné à préparer une forme amorphe stable de valsartan et, dans ce contexte, une forme amorphe de valsartan produite au moyen de ces procédés. La présente invention concerne en outre un nouveau procédé destiné à obtenir des cristaux stables de forme I de valsartan.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjb8KwjAYxLs4iPoOAQfr8EH_KNUxLSkppPlCGtQoUorESbRQd1_diD6A03HH7-7GwUvijglSaNsYKkQlGSlR1w3BkoTNEiSEMRRU53iwkEDNDLcClEYFMVjxARSThkr0sYRTsvAFDoYZTY8oYP2B8goUZ9ITK2-_G2egtX-bBqNrdxvc7KeTYF4yU3Bw_aN1Q99d3N092z0mUZRFcbbZZjRN_6PehBI78w</recordid><startdate>20091015</startdate><enddate>20091015</enddate><creator>DOSHI, VAIBHAV, CHINUBHAI</creator><creator>KUMAR, ASHOK</creator><creator>BHAYANI, PRITI, JAYESH</creator><creator>JHA, MUKESH, SUBHODH</creator><creator>NIMBALKAR, MANMOHAN, MADHAVRAO</creator><scope>EVB</scope></search><sort><creationdate>20091015</creationdate><title>NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE</title><author>DOSHI, VAIBHAV, CHINUBHAI ; KUMAR, ASHOK ; BHAYANI, PRITI, JAYESH ; JHA, MUKESH, SUBHODH ; NIMBALKAR, MANMOHAN, MADHAVRAO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2007017897A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>DOSHI, VAIBHAV, CHINUBHAI</creatorcontrib><creatorcontrib>KUMAR, ASHOK</creatorcontrib><creatorcontrib>BHAYANI, PRITI, JAYESH</creatorcontrib><creatorcontrib>JHA, MUKESH, SUBHODH</creatorcontrib><creatorcontrib>NIMBALKAR, MANMOHAN, MADHAVRAO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DOSHI, VAIBHAV, CHINUBHAI</au><au>KUMAR, ASHOK</au><au>BHAYANI, PRITI, JAYESH</au><au>JHA, MUKESH, SUBHODH</au><au>NIMBALKAR, MANMOHAN, MADHAVRAO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE</title><date>2009-10-15</date><risdate>2009</risdate><abstract>Disclosed herein is novel crystalline forms of Valsartan namely, a crystalline form designated as Form A, and its solvates thereof, novel crystalline form of Valsartan designated as Form B and solvates thereof, novel crystalline form of Valsartan designated as Form C and solvates thereof, novel crystalline form of Valsartan designated as Form D and its solvates thereof, processes for their preparation, pharmaceutical compositions containing these polymorphs and their use in medicine. The present invention further discloses a novel process for preparing a stable amorphous form of Valsartan and in this connection to amorphous form of Valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of Valsartan.
L'invention concerne de nouvelles formes cristallines de valsartan, soit une forme cristalline désignée sous le nom de forme A et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme B et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme C et ses solvates, une nouvelle forme cristalline de valsartan désignée sous le nom de forme D et ses solvates, des procédés pour leur préparation, des compositions pharmaceutiques contenant ces polymorphes ainsi que leur utilisation en médecine. La présente invention concerne également un nouveau procédé destiné à préparer une forme amorphe stable de valsartan et, dans ce contexte, une forme amorphe de valsartan produite au moyen de ces procédés. La présente invention concerne en outre un nouveau procédé destiné à obtenir des cristaux stables de forme I de valsartan.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2007017897A3 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | NOVEL CRYSTALLINE FORMS OF (S)-N-(1-CARBOXY-2-METHYL-PROP-1-YL)-N-PENTANOYL-N-[2'-(1H-TETRAZOL-5-YL)BI-PHENYL-4-YLMETHYL]-AMINE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A29%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DOSHI,%20VAIBHAV,%20CHINUBHAI&rft.date=2009-10-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2007017897A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |